DEFINITIONS
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Time-to-clearance of bacteremia was defined as number of days between the first positive blood 116 culture and the first negative blood culture for the causative agents of IE. Significant creatine 117 phosphokinase (CPK) elevation was defined in our study as an elevation greater than 400 IU/L 118 (normal range <50 IU/ml). This CPK metric is based on data from a prior study of daptomycin 119 usage in S. aureus bacteremia [8] . CPK levels greater than 400 IU/L in the 72 hours immediately 120 after surgery were not reported. Peripheral nervous system disorders were defined as and eosinophilic pneumonia [8-9, 13, 16] . 6-month mortality were common outcomes in our study, and the use of an adjusted odds ratio 153 may overstate the relative risk, a log-binomial model was used to compute the adjusted relative 154 risk of these outcomes. Variables found to have the strongest univariable association with in-155 hospital mortality and 6-month mortality (p <0.05) were entered into the final model in order to 156 have at least 10 events per variable. The variable "Cohort A" was entered in the models to assess 8
RESULTS
165
Of the 1,112 patients available in the ICE-Plus and ICE DS databases, there were 996 patients 166 with definite IE. IE was due to S. aureus, CNS or E. faecalis in 441 of these patients: 49 were 167 treated with daptomycin and 392 were treated with a different antibiotic regimen. Of the patients 168 treated with daptomycin, the following were excluded: polymicrobial infection (n=1), non-left 169 sided IE (n=11), and duration of treatment <50% of the duration recommended by the AHA 170 (n=8). Of the 392 patients not receiving daptomycin, the following were excluded: polymicrobial 171 IE (n=16), non-left sided IE (n=102), age <16 years (n=4), and antibiotic regimens which did not 172 meet study criteria, as described above (n=121). Thus, there were 29 evaluable subjects in
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Cohort A and 149 patients in Cohort B of this study (Figure 1) In-hospital mortality and 6-month mortality 225 While several variables were associated with in-hospital mortality on univariable analysis (Table   226 5), log-binomial analysis demonstrated that in-hospital mortality was independently associated (75.8% of the study population). The 6-month mortality rate was significantly associated with 231 age >60 year-old, moderate-to-severe renal disease, diabetes and moderate-to-severe liver 232 disease. Non-stroke embolization was significantly more common among patients alive at 233 6-months. Of these variables, only moderate-to-severe liver disease was independently 234 associated with 6-month mortality (RR 1.7; 95% CI 1.3-1.9; p-value 0.03). Daptomycin 235 treatment did not differentially impact 6-month mortality in comparison to SOC therapy.
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Similarly, surgical therapy was not associated with in-hospital or 6-month mortality ( (Table 7) .
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In this study, in-hospital and 6-month mortality rates were similar among patients treated MRSA IE who received daptomycin also had a numerically lower mortality rate (both in-hospital 290 and 6-month mortalities) than those treated with SOC antimicrobials, although this did not reach 291 statistical significance. We hypothesize that these latter findings are at least partly due to a faster 292 bactericidal effect of daptomycin than the SOC comparator, vancomycin, which is known for its
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'slow bactericidal' effect in vitro [24, 25] and substantial clinical failure rate in vivo [26] . This study has several noteworthy limitations. The relatively small number of patients in 320 the daptomycin treatment group in this study limits our ability to detect significant differences 321 between groups. Since this is an observational cohort study, we cannot make any definitive 322 inferences between daptomycin dose-strategies and patient outcomes. Data for this study were 323 derived from sites in the ICE collaboration which are mostly tertiary care centers with extensive 324 expertise in IE: therefore, the results of this study may be subject to "center bias". Finally, our 325 study lacked detailed information about tolerability of the antibiotic regimens in the SOC group.
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In conclusion, our findings suggest that higher-dose daptomycin may be a valid alternative to 327 SOC antibiotics in the treatment of left-sided IE due to susceptible strains of S. aureus, CNS, and 328 E. faecalis. Although the present study shows that daptomycin achieved favorable clinical 329 outcomes in a difficult-to-treat subset of patients, further studies are needed to validate our 330 findings and to determine the role of daptomycin in this specific sub-group of IE patients. 
